Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $13.9850 (0.61%) ($13.8250 - $14.2050) on Wed. Sep. 16, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.82% (three month average) | RSI | 48 | Latest Price | $13.9850(0.61%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 0.1% a day on average for past five trading days. | Weekly Trend | FOLD declines -2.9% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(53%) IWO(50%) XBI(50%) IWM(47%) IWC(45%) | Factors Impacting FOLD price | FOLD will decline at least -1.41% in a week (0% probabilities). VIXM(-29%) VXX(-14%) UUP(-12%) UNG(-4%) IGOV(-4%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.41% (StdDev 2.82%) | Hourly BBV | 0.6 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $6.5(-53.52%) | Inflection Point | Yes | Resistance Level | $14.06 | 5 Day Moving Average | $13.57(3.06%) | 10 Day Moving Average | $13.67(2.3%) | 20 Day Moving Average | $14.06(-0.53%) | To recent high | -12% | To recent low | 8.6% | Market Cap | $3.611b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |